This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Further investigation with an intermediate probability of asthma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Patients with airways obstruction

Tests of peak expiratory flow variability, lung volumes, gas transfer, airway hyper-responsiveness and airway inflammation are of limited value in discriminating patients with established airflow obstruction due to asthma from those whose airflow obstruction is due to other conditions.Patients may have more than one cause of airflow obstruction, which complicates the interpretation of any test. In particular, asthma and chronic obstructive pulmonary disease (COPD) commonly coexist

  • offer patients with airways obstruction and intermediate probability of asthma a reversibility test and/or a trial of treatment for a specified period:
    • if there is significant reversibility, or if a treatment trial is clearly beneficial treat as asthma
    • if there is insignificant reversibility and a treatment trial is not beneficial, consider tests for alternative conditions

Patients without airways obstruction

In patients with a normal or near-normal spirogram it is more useful to look for evidence of airway hyper-responsiveness and/or airway inflammation.These tests are sensitive so normal results provide the strongest evidence against a diagnosis of asthma

  • in patients without evidence of airways obstruction and with an intermediate probability of asthma, arrange further investigations before commencing treatment

  • tests of airway responsiveness have been useful in research but are not yet widely available in everyday clinical practice
    • most widely used method of measuring airway responsiveness relies on measuring response in terms of change in FEV1 a set time after inhalation of increasing concentrations of histamine or methacholine. The agent can be delivered by breath-activated dosimeter, via a nebuliser using tidal breathing, or via a hand held atomiser
      • response is usually quantified as the concentration (or dose) required to cause a 20% fall in FEV1 (PC20 or PD20) calculated by linear interpolation of the log concentration or dose-response curve

  • eosinophilic airway inflammation can be assessed non-invasively using the induced sputum differential eosinophil count or the exhaled nitric oxide concentration (FENO)
    • a raised sputum eosinophil count (>2%) or FENO (>25 ppb at 50 ml/sec) is seen in 70-80% of patients with untreated asthma
      • neither finding is specifi c to asthma: 30-40% of patients with chronic cough and a similar proportion of patients with COPD have abnormal results
      • there is growing evidence that measures of eosinophilic airway inflammation are more closely linked to a positive response to corticosteroids than other measures even in patients with diagnoses other than asthma

Consider performing chest X-ray in any patient presenting atypically or with additional symptoms or signs. Additional investigations such as full lung function tests, blood eosinophil count, serum IgE and allergen skin prick tests may be of value in selected patients.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.